# CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

Study · id `cardio:ct-nct04369664` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04369664](<https://clinicaltrials.gov/study/NCT04369664>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04369664

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

## Technical summary

Registry record NCT04369664. Non-randomized; no masking; primary purpose treatment. Start 2020-08-12 (actual); primary completion 2023-09-25 (actual). Results posted on 2024-10-17.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 151 participants (enrolled count; ClinicalTrials.gov record NCT04369664, source copy `cardio:ctgov-nct04369664-2024-10-17`, retrieved 2026-10-26)
- Started: 2020-08-12 (actual) (ClinicalTrials.gov record NCT04369664, source copy `cardio:ctgov-nct04369664-2024-10-17`, retrieved 2026-10-26)
- Primary completion: 2023-09-25 (actual) (ClinicalTrials.gov record NCT04369664, source copy `cardio:ctgov-nct04369664-2024-10-17`, retrieved 2026-10-26)
- Completion: 2023-10-19 (actual) (ClinicalTrials.gov record NCT04369664, source copy `cardio:ctgov-nct04369664-2024-10-17`, retrieved 2026-10-26)
- Results first posted: 2024-10-17 (ClinicalTrials.gov record NCT04369664, source copy `cardio:ctgov-nct04369664-2024-10-17`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04369664, source copy `cardio:ctgov-nct04369664-2024-10-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04369664-2024-10-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
- Acronym: CHORD
- Condition: Type 2 Diabetes
- Intervention (Drug): Statin
- Intervention (Drug): PCSK9 inhibitor
- Intervention (Drug): Ezetimibe 10mg
- Lead sponsor: NYU Langone Health
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: NYU Langone Health (`cardio:org-nyu-langone-health`)

## Provenance

Content hash: 5b581c1cc8aac8d38453dbcb2ac8d49b93cfb102ca0fed49611be748422001f4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
